SCHEMBL2895650

SCHEMBL2895650

CC(C)n1c(=O)c(O)c2n(c1=O)CCN(Cc1ccc(F)c(Cl)c1)C2=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.38
ERCC1 P07992 1/20 0.38
ERCC4 Q92889 1/20 0.38
GRM2 Q14416 2/20 0.37
HTR2A P28223 1/20 0.37
CYP2D6 P10635 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
TP53 P04637 1/20 0.35
CLPP Q16740 1/20 0.35
TNIK Q9UKE5 1/20 0.35
PIK3CA P42336 1/20 0.34
PGR P06401 1/20 0.34
KCNH2 Q12809 1/20 0.34
P2RX7 Q99572 1/20 0.34
P2RX3 P56373 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3907766 0.81 ERCC1 (0.44) ERCC1ERCC4GRM2HTR2ACLPP
SCHEMBL2895523 0.81 P2RX7 (0.51) CYP2D6P2RX7KDM4EALDH1A1HPGD
SCHEMBL2898871 0.81 HDAC1 (0.40) CYP2D6HRH3CLPP
SCHEMBL16185207 0.79 ERCC1 (0.34) MAOBERCC1ERCC4GRM2HTR2A
SCHEMBL5522450 0.78 ERCC1 (0.39) ERCC1ERCC4CLPPPIK3CAKCNH2
SCHEMBL4743344 0.77 CLPP (0.39) MAOBERCC1ERCC4GRM2HTR2A
SCHEMBL5529791 0.77 ERCC1 (0.36) ERCC1ERCC4GRM2HTR2ATP53
SCHEMBL3906273 0.77 ALDH1A1 (0.40) MAOBERCC1ERCC4HRH3CLPP
SCHEMBL16180376 0.77 PIK3CB (0.34) ERCC1ERCC4GRM2HTR2ATP53
SCHEMBL2898100 0.76 MEN1 (0.40) GRM2CYP2D6HRH3TP53KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP MAOB 1239/4885ERCC1 174/4885ERCC4 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.